Page 19 - 80_02

Carlos
Alonso,
Manuel
Soto

ACKNOWLEDGEMENTS

This
review
gathers
data
from
already
published
paper.
It
was
supported
by

grants
from
Ministerio
de
Ciencia
e
Innovación
FIS
PI11/00095
and
from
the

Instituto
de
Salud
Carlos
III
within
the
Network
of
Tropical
Diseases
Research
(VI
P

I+D+I
2008-­-2011,
ISCIII
-­-Subdirección
General
de
Redes
y
Centros
de
Investigación

Cooperativa
(RD12/0018/0009)).
Funding
from
Laboratorios
Leti
and
an

institutional
grant
from
Fundación
Ramón
Areces
are
also
acknowledged.

REFERENCES

1
Mauricio,
I.
L.;
Stothard,
J.
R.;
Miles,
M.
A.
The
strange
case
of
Leishmania
chagasi.

Parasitology
Today
16,
188-­-189
(2000).

2
Murray,
H.
W.;
Berman,
J.
D.;
Davies,
C.
R.;
Saravia,
N.
G.
Advances
in
Leishmaniasis.
Lancet

366,
1561-­-1577
(2005).

3
Herwaldt,
B.
L.
Leishmaniasis.
Lancet
354,
1191-­-1199
(1999).

4
Mutiso,
J.
M.;
Macharia,
J.
C.;
Kiio,
M.
N.;
Ichagichu,
J.
M.;
Rikoi,
H.;
Gicheru,
M.
M.

Development
of
Leishmania
vaccines:
predicting
the
future
from
past
and
present

experience.
Journal
of
Biomedical
Research
27,
85-­-102
(2013).

5
Gramiccia,
M.;
Gradoni,
L.
The
current
status
of
zoonotic
leishmaniases
and
approaches
to

disease
control.
International
Journal
of
Parasitology
35,
1169-­-1180
(2005).

6
Reis,
A.
B.;
Giunchetti,
R.
C.;
Carrillo,
E.;
Martins-­-Filho,
O.
A.;
Moreno,
J.
Immunity
to

Leishmania
and
the
rational
search
for
vaccines
against
canine
leishmaniasis.
Trends
in

Parasitology
26,
341-­-349
(2010).

7
Baneth,
G.;
Koutinas,
A.
F.;
Solano-­-Gallego,
L.;
Bourdeau,
P.;
Ferrer,
L.
Canine
leishmaniosis:

new
concepts
and
insights
on
an
expanding
zoonosis:
part
one.
Trends
in
Parasitology
24,

324-­-330
(2008).

8
Murray,
H.
W.
Endogenous
interleukin-­-12
regulates
acquired
resistance
in
experimental

visceral
leishmaniasis.
The
Journal
of
Infectious
Diseases
175,
1477-­-1479
(1997).

9
de
Oliveira,
C.
I.;
Brodskyn,
C.
I.
The
immunobiology
of
Leishmania
braziliensis
infection.

Frontiers
in
Immunology
3,
145
(2012).

10
Bertholet,
S.;
Goto,
Y.;
Carter,
L.;
Bhatia,
A.;
Howard,
R.
F.;
Carter,
D.;
Coler,
R.
N.;
Vedvick,
T.

S.;
Reed,
S.
G.
Optimized
subunit
vaccine
protects
against
experimental
leishmaniasis.

Vaccine
27,
7036-­-7045
(2009).

11
Beaumier,
C.
M.;
Gillespie,
P.
M.;
Hotez,
P.
J.;
Bottazzi,
M.
E.
New
vaccines
for
neglected

parasitic
diseases
and
dengue.
Translational
Research
162,
144-­-155
(2013).

12
Dantas-­-Torres,
F.
Leishmune
vaccine:
the
newest
tool
for
prevention
and
control
of
canine

visceral
leishmaniosis
and
its
potential
as
a
transmission-­-blocking
vaccine.
Veterinary

Parasitology
141,
1-­-8
(2006).

13
Fernandes,
A.
P.;
Coelho,
E.
A.;
Machado-­-Coelho,
G.
L.;
Grimaldi,
G.,
Jr.;
Gazzinelli,
R.
T.

Making
an
anti-­-amastigote
vaccine
for
visceral
leishmaniasis:
rational,
update
and

perspectives.
Current
Opinion
in
Microbiology
15,
476-­-485
(2012).

14
Bongiorno,
G.;
Paparcone,
R.;
Manzillo,
V.
F.;
Oliva,
G.;
Cuisinier,
A.
M.;
Gradoni,
L.

Vaccination
with
LiESP/QA-­-21
(CaniLeish)
reduces
the
intensity
of
infection
in

Phlebotomus
perniciosus
fed
on
Leishmania
infantum
infected
dogs-­-A
preliminary

xenodiagnosis
study.
Veterinary
Parasitology
97
691-­-695
(2013).

15
Moreno,
J.;
Vouldoukis,
I.;
Martin,
V.;
McGahie,
D.;
Cuisinier,
A.
M.;
Gueguen,
S.
Use
of
a

LiESP/QA-­-21
vaccine
(CaniLeish)
stimulates
an
appropriate
Th1-­-dominated
cell-­-mediated

immune
response
in
dogs.
PLoS
Neglected
Tropical
Diseases
6,
e1683
(2012)

16
Melby,
P.
C.;
Yang,
Y.
Z.;
Cheng,
J.;
Zhao,
W.
Regional
differences
in
the
cellular
immune

response
to
experimental
cutaneous
or
visceral
infection
with
Leishmania
donovani.

Infection
and
Immunity
66,
18-­-27
(1998).

17
de
Oliveira,
C.
I.;
Nascimento,
I.
P.;
Barral,
A.;
Soto,
M.;
Barral-­-Netto,
M.
Challenges
and

perspectives
in
vaccination
against
leishmaniasis.
Parasitology
International
58,
319-­-324

(2009).

258